$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000117184317001159 Filed on February 27, 2017

Income Statement

Concept	2017 Q1	2015 Q4	2015 Q3
Revenue	$9.437M	$4.602M	$10.99M
YoY Change	95.79%	-15.5%	239.31%
Cost Of Revenue	$290.0K	$30.00K	$1.346M
YoY Change		-25.0%
Gross Profit	$9.140M	$4.570M	$9.641M
YoY Change	89.63%	-15.37%	197.75%
Gross Profit Margin	96.85%	99.3%	87.75%
Selling, General & Admin	$3.058M	$2.720M	$2.731M
YoY Change	-4.79%	32.68%	50.88%
% of Gross Profit	33.46%	59.52%	28.33%
Research & Development	$16.77M	$19.05M	$20.07M
YoY Change	-18.51%	2.92%	53.94%
% of Gross Profit	183.48%	416.85%	208.14%
Depreciation & Amortization	$172.0K	$40.00K	$50.00K
YoY Change	265.96%	0.0%	25.0%
% of Gross Profit	1.88%	0.88%	0.52%
Operating Expenses	$19.83M	$21.77M	$22.80M
YoY Change	-16.66%	5.89%	74.88%
Operating Profit	-$10.69M	-$17.20M	-$13.16M
YoY Change	-43.9%	13.46%	13.37%
Interest Expense	$2.100M	-$940.0K	$1.241M
YoY Change	42.86%	-127.01%	1.97%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.22M	-$18.14M	-$14.62M
YoY Change	-37.71%	55.44%	67.47%
Income Tax
% Of Pretax Income
Net Earnings	-$14.22M	-$18.14M	-$14.62M
YoY Change	-37.72%	55.37%	67.46%
Net Earnings / Revenue	-150.67%	-394.07%	-133.08%
Basic Earnings Per Share		-$0.25	-$0.20
Diluted Earnings Per Share	-$189.2K	-$0.25	-$0.20
COMMON SHARES
Basic Shares Outstanding	73.96M		73.24M
Diluted Shares Outstanding	75.17M		73.26M

Balance Sheet

Concept	2017 Q1	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.68M	$51.56M	$70.33M
YoY Change	175.52%	-29.14%	-44.67%
Cash & Equivalents	$75.16M	$28.90M	$46.63M
Short-Term Investments	$23.52M	$22.66M	$23.70M
Other Short-Term Assets	$4.600M	$4.400M	$7.100M
YoY Change	-13.21%	-31.25%	51.06%
Inventory	$655.0K	$1.612M
Prepaid Expenses
Receivables	$9.564M	$6.243M	$4.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$113.5M	$63.79M	$84.50M
YoY Change	125.09%	-28.6%	-37.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.753M	$5.149M	$1.146M
YoY Change	16.63%	2387.44%	473.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.800M	$47.70M	$36.10M
YoY Change	-90.75%	16.06%	11933.33%
Other Assets	$2.271M	$5.468M	$5.239M
YoY Change	-16.32%	-9.34%	249.27%
Total Long-Term Assets	$16.01M	$58.57M	$54.45M
YoY Change	-69.48%	23.21%	2622.7%
TOTAL ASSETS
Total Short-Term Assets	$113.5M	$63.79M	$84.50M
Total Long-Term Assets	$16.01M	$58.57M	$54.45M
Total Assets	$129.5M	$122.4M	$139.0M
YoY Change	25.89%	-10.6%	1.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.433M	$9.307M	$3.782M
YoY Change	-29.36%	226.68%	64.43%
Accrued Expenses	$11.34M	$16.24M	$23.03M
YoY Change	-34.59%	43.32%	43.02%
Deferred Revenue
YoY Change
Short-Term Debt	$28.40M	$27.80M	$30.00M
YoY Change	1.79%	-7.33%	0.0%
Long-Term Debt Due	$1.300M
YoY Change
Total Short-Term Liabilities	$58.56M	$62.26M	$64.44M
YoY Change	-7.16%	8.66%	29.41%
LONG-TERM LIABILITIES
Long-Term Debt	$24.30M	$2.400M	$0.00
YoY Change	872.0%
Other Long-Term Liabilities	$8.100M	$10.00M	$10.30M
YoY Change	-14.74%	156.41%	171.05%
Total Long-Term Liabilities	$32.40M	$12.40M	$10.30M
YoY Change	170.0%	217.95%	171.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.56M	$62.26M	$64.44M
Total Long-Term Liabilities	$32.40M	$12.40M	$10.30M
Total Liabilities	$91.00M	$74.60M	$74.10M
YoY Change	21.17%	21.9%	37.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$580.3M	-$510.9M	-$492.8M
YoY Change	8.72%	9.19%
Common Stock	$804.0K	$734.0K	$733.0K
YoY Change	9.09%	1.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.53M	$47.72M	$64.05M
YoY Change
Total Liabilities & Shareholders Equity	$129.5M	$122.4M	$139.0M
YoY Change	25.89%	-10.6%	1.35%

Cashflow Statement

Concept	2017 Q1	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	-$14.22M	-$18.14M	-$14.62M
YoY Change	-37.72%	55.37%	67.46%
Depreciation, Depletion And Amortization	$172.0K	$40.00K	$50.00K
YoY Change	265.96%	0.0%	25.0%
Cash From Operating Activities	-$8.527M	-$14.83M	-$12.66M
YoY Change	-54.74%	6.77%	47.21%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$4.040M	-$150.0K
YoY Change	-100.0%	5671.43%	400.0%
Acquisitions
YoY Change
Other Investing Activities	$12.88M	$1.060M	-$18.00M
YoY Change	115.75%	-102.0%	-467.35%
Cash From Investing Activities	$14.13M	-$2.980M	-$18.14M
YoY Change	421.51%	-94.39%	-472.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$47.75M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	48.70M	90.00K	640.0K
YoY Change	34685.71%	-75.0%	-81.07%
NET CHANGE
Cash From Operating Activities	-8.527M	-14.83M	-12.66M
Cash From Investing Activities	14.13M	-2.980M	-18.14M
Cash From Financing Activities	48.70M	90.00K	640.0K
Net Change In Cash	54.31M	-17.72M	-30.16M
YoY Change	-439.62%	-73.4%	8517.14%
FREE CASH FLOW
Cash From Operating Activities	-$8.527M	-$14.83M	-$12.66M
Capital Expenditures	$0.00	-$4.040M	-$150.0K
Free Cash Flow	-$8.527M	-$10.79M	-$12.51M
YoY Change	-45.27%	-21.92%	45.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	7427000
CY2015Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	10398000
CY2016	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS INC
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72901000
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66773000
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73955169
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016Q2	dei	Entity Public Float EntityPublicFloat	206175247
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Trading Symbol TradingSymbol	bcrx
CY2016Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	705000
CY2015Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	549000
CY2016	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	523000
CY2015	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	570000
CY2014	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	150000
CY2016Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	77000
CY2015Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	292000
CY2016Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	8926000
CY2015Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	28395000
CY2016Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
CY2015Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	19288000
CY2016	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	14402000
CY2015	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	39580000
CY2014	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	10550000
CY2016	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	14402000
CY2015	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	39580000
CY2014	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	10550000
CY2016Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	199000
CY2015Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	265000
CY2016	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-71000
CY2015	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	102000
CY2014	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-59000
CY2016	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	1798000
CY2015	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	4307000
CY2014	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
CY2016Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	406000
CY2016Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	2606000
CY2016Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	4649000
CY2016Q4	bcrx	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear	6880000
CY2016	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	559000
CY2015	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	330000
CY2014	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	373000
CY2016	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations	329000
CY2015	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations
CY2014	bcrx	Increase Decrease In Financing Lease Obligations IncreaseDecreaseInFinancingLeaseObligations
CY2016Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2704000
CY2015Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2375000
CY2015Q1	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	150000000
CY2014	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	1965000
CY2015	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	2217000
CY2016	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	2248000
CY2014	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	88000
CY2015	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	33000
CY2016	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	717000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4269000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9307000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8768000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6243000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10836000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16237000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	242000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	242000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4917000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14205000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-206000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	566913000
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	558113000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10177000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9705000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8487000
CY2015	us-gaap	Advertising Expense AdvertisingExpense	103000
CY2014	us-gaap	Advertising Expense AdvertisingExpense	290000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8487000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9705000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10177000
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	558000
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	439000
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	439000
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1226000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3524000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3991000
CY2016Q4	us-gaap	Assets Assets	89847000
CY2015Q4	us-gaap	Assets Assets	122359000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	66987000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	63794000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41472000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	70347000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	41407000
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	70261000
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	32546000
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	22664000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32546000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	22664000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	8926000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	47683000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25641000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	33376000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28899000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54540000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21164000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6795000
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73782000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73355000
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73782000
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73355000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	738000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	734000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54950000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43095000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45323000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2297000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1368000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	74960000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	87701000
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	59379000
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	85000
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	90000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2089000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2668000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	244000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	329000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2022000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2163000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8184000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9674000
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3484000
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4240000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	227134000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	207876000
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	158618000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	142836000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2849000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2590000
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1054000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	53231000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48551000
CY2016Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	1415000
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8952000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8605000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	225045000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	205208000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	674000
CY2015Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	2668000
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	504000
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	366000
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	361000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	483000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	180000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	177000
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	425000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	424000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14541000
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	15655000
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-17000
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-27000
CY2016	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-843000
CY2015	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1090000
CY2014	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	5487000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2016	us-gaap	Interest Expense InterestExpense	6487000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	560000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	258000
CY2015	us-gaap	Interest Expense InterestExpense	5200000
CY2014	us-gaap	Interest Expense InterestExpense	4998000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8990000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6746000
CY2016Q4	us-gaap	Inventory Net InventoryNet	500000
CY2015Q4	us-gaap	Inventory Net InventoryNet	1612000
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	822000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-218000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-115000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20339000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17312000
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1080000
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1012000
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	22000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19300000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15057000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15816000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1057000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19837000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1173000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-819000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1286000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4681000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10454000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	748000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10524000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	13676000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4656000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1631000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1199000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4429000
CY2016	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	811000
CY2015	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-564000
CY2014	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	5487000
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2244000
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	717000
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2162000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1112000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	929000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	683000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3702000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-637000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2093000
CY2016	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2525000
CY2015	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3247000
CY2014	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7375000
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-66000
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1462000
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000
CY2016	us-gaap	Interest And Other Income InterestAndOtherIncome	793000
CY2015	us-gaap	Interest And Other Income InterestAndOtherIncome	535000
CY2014	us-gaap	Interest And Other Income InterestAndOtherIncome	93000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	500000
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1612000
CY2015	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	53830000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89847000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122359000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54360000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62257000
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	22777000
CY2015Q4	us-gaap	Line Of Credit LineOfCredit
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	23000000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2300000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	6900000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6900000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	6900000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23304000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5479000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	111907000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	23339000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18004000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-39980000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-53438000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13116000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-38551000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-45189000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-43019000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-55144000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-22832000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-16281000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-11528000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-4503000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-15164000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	4901000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-14621000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-18135000
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	28243000
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	27804000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-48607000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-39444000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-45771000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6151000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	871000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	478000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	653000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	822000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	838000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2489000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	721000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	664000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	633000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1981000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4522000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3813000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5468000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-134000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-76000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	194000
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	194000
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-76000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-134000
CY2016	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	14106000
CY2014	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	73875000
CY2016	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5277000
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5122000
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	106000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1438000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2674000
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"> </div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company adopted Accounting Standards Update No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">03,</div> <div style="display: inline; font-style: italic;">Interest – Imputation of Interest (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30):</div> Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,196</div> classified as other current assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> have been reclassified and netted against non-recourse notes payable to conform to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> presentation.</div></div></div></div>
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42652000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9922000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106600000
CY2016	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	22658000
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42410000
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	34000000
CY2016	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures	4000
CY2015	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures
CY2014	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	317000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5479000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5307000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14839000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19354000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5149000
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8768000
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6243000
CY2016	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	11000
CY2015	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	13000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61008000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72758000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51796000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1546000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1612000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566061000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510917000
CY2016	us-gaap	Revenues Revenues	26353000
CY2015	us-gaap	Revenues Revenues	48257000
CY2014	us-gaap	Revenues Revenues	13608000
CY2016	us-gaap	Royalty Expense RoyaltyExpense	402000
CY2015	us-gaap	Royalty Expense RoyaltyExpense	528000
CY2014	us-gaap	Royalty Expense RoyaltyExpense	121000
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	9682000
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	2386000
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	3025000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2269000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6291000
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33000
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	26353000
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	48257000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	13608000
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	4820000
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	4787000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7763000
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	8983000
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	6826000
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	25842000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	10987000
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4602000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11253000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13047000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7461000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	8487000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	9705000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	10177000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	22000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	593000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	163000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	34000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.82
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.014
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3750000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3800000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1082000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2362000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	16000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2273000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.21
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.50
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.55
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	88000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	33000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	717000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.83
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.87
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.78
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	235000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1965000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2217000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2248000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2248000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.17
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8986000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9605000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10671000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12095000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.99
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-1126000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	75635000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	47724000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1578000
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.78
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.36
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.63
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.99
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.52
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.20
CY2016	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6499000
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	12095000
CY2016	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	18
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4863000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5598000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.79
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.40
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.40
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1278000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.99
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.66
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.55
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y219D
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1258000
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1118000
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	107000
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	310000
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	355000
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	329000
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	106600000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4997000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5124000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-12000
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	56000
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	102000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3085000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	472000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4255000
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1170000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2616000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div>
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73699000

Files In Submission

Name	View Source	Status
0001171843-17-001159-index-headers.html	Edgar Link	pending
0001171843-17-001159-index.html	Edgar Link	pending
0001171843-17-001159.txt	Edgar Link	pending
0001171843-17-001159-xbrl.zip	Edgar Link	pending
bcrx-20161231.xml	Edgar Link	completed
bcrx-20161231.xsd	Edgar Link	pending
bcrx-20161231_cal.xml	Edgar Link	unprocessable
bcrx-20161231_def.xml	Edgar Link	unprocessable
bcrx-20161231_lab.xml	Edgar Link	unprocessable
bcrx-20161231_pre.xml	Edgar Link	unprocessable
exh1074_1.jpg	Edgar Link	pending
exh1077_1.jpg	Edgar Link	pending
exh1077_2.jpg	Edgar Link	pending
exh1077_3.jpg	Edgar Link	pending
exh_1074.htm	Edgar Link	pending
exh_1077.htm	Edgar Link	pending
exh_21.htm	Edgar Link	pending
exh_23.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10k_022717p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2017 Q1 Form 10-K Financial Statement

#000117184317001159 Filed on February 27, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2017 Q1 Form 10-K Financial Statement

#000117184317001159 Filed on February 27, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx